Skip to content

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Impact and Evaluation of the Management of Iron Deficiency With or Without Anemia in Patients With Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03625661
Acronym
CAMARA
Enrollment
257
Registered
2018-08-10
Start date
2014-02-02
Completion date
2017-06-12
Last updated
2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron Deficiency Anemia

Keywords

Treatment Related Cancer,iron deficiency

Brief summary

In oncology, anemia is a frequent symptom, leading to complication of patient management for, more or less, a long term but often poorly evaluated by medical teams. In oncology, anemia is induced by multiple causes. Iron deficiency appears to be a leading cause of anemia, especially in people with solid cancer. Iron deficiency is characterized by a low level of iron . Iron is a trace element required for life. It is a major component of hemoglobin allowing the transport of oxygen in red blood cells. There are in fact 2 types of iron deficiency: an absolute iron deficiency with a deficiency of true iron and a functional iron deficiency. Since end of January 2014, intravenous iron-based injections have been reclassified for cancer patients at ICO Paul Papin. The monitoring of iron deficiency with or without anemia is currently done in our institute, the ICO-Paul Papin. There is a procedure for the management of anemia with or without iron deficiency but there is still no traceability of treatments performed, their compliance or even their impact on the rate hemoglobin and the quality of life of patients during their treatment. This observatory also makes it possible to evaluate the impact of this treatment on the quality of life of the patients and thus allows them a personalized care of the tiredness during their treatment

Detailed description

The study is for patients with iron deficiency and / or anemia during treatment for cancer These patients will receive ferinject. Patients will perform functional assessments and complete quality of life questionnaires, when the ferinject will be injected, then at 1 month and 6 months. Patients will be followed for 6 months in the study

Interventions

DRUGFerinject

Ferinject 50mg/ml, one injection

Sponsors

Institut Cancerologie de l'Ouest
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

cohort study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Patient with cancer regardless of the location * Patient with specific treatment (chemotherapy +/- targeted therapy and / or radiotherapy, hormone therapy or surgery) * Patient with Functional Iron Deficiency or absolute with or without anemia * Having given written informed consent prior to any procedure related to the study.

Exclusion criteria

* Patient in a palliative situation not receiving specific treatment for their cancer * Patient is willing and able to comply with the protocol for the duration of the study including all scheduled treatment, visits and examinations * Patient with myeloproliferative disease * Contraindication to treatments for iron deficiency and / or anemia * Pregnant woman, parturient or nursing mothers * Patient has no valid health insurance * Disorder precluding understanding of trial information or informed consent

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the quality of life of patients with iron deficiency with or without anemia during treatment for their cancer42 monthsObtained with the quality of life with the FACT-An questionnaire.

Secondary

MeasureTime frameDescription
Estimation of the proportion of absolute iron deficiency42 monthsAbsolute iron deficiency is defined by a ferritin level \<300 μg / L and a transferrin saturation coefficient \<20%.
Estimation of the proportion of functional iron deficiency42 monthsFunctional iron deficiency is defined by a ferritin level \<800 μg / L and a Transferrin Saturation Coefficient \<20%.
Estimation of the proportion of iron deficiency as a whole42 monthsAddition of proportion of iron deficiency
Estimation of the proportion of anemia as a whole42 monthsAddition of proportion of asymptomatic anemia and symptomatic anemia
Estimation of the proportion of asymptomatic anemia42 monthsAsymptomatic anemia is defined as hemoglobin \<12 g / dL without clinical signs.
Estimation of the proportion of undernourished patients42 monthsThe diagnosis of malnutrition will be done by calculating BMI (\<18.5 si - 70 years old and \<21 from 70 years old)
Estimation of the evolution of the functional capacities of the patient42 monthsEstimated by functional questionnaire (Berg Balanced Scale test)
Estimation proportion of symptomatic anemia42 monthsSymptomatic anemia is defined as hemoglobin \<12 g / dL associated with pallor and anoxic functional symptoms

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026